Findings

What do systematic reviews say?

10 questions · 11 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 4 · 36.4%Very low 4 · 36.4%Low 0 · 0%Moderate 3 · 27.3%High 0 · 0%

Oral dehydroepiandrosterone vs placebo

Complete response · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone showed no clear difference in primary outcome: complete clinical response compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 1.11 [1, 1.22]
1 study · 381 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Oral dehydroepiandrosterone vs placebo

Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.66]
1 study · 381 participants
Moderate

Oral dehydroepiandrosterone vs placebo

Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus

Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
RR 10.5 [3.26, 33.75]
1 study · 381 participants
Moderate

Oral DHEA vs control subgrouped by differing routes of administration

QoL · Women in the peri‐ or postmenopausal phase

2 findings from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low
Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Oral DHEA vs control subgrouped by differing routes of administration

Side effects: acne ‐ oral administration · Women in the peri‐ or postmenopausal phase

It is very uncertain whether oral DHEA changes side effects: acne ‐ oral administration compared with control subgrouped by differing routes of administration (very low certainty).

1 finding from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
OR 2.16 [0.47, 9.96]
3 studies · 136 participants
Very low

Oral DHEA vs control subgrouped by differing routes of administration

Side effects: acne ‐ skin application · Women in the peri‐ or postmenopausal phase

It is very uncertain whether oral DHEA changes side effects: acne ‐ skin application compared with control subgrouped by differing routes of administration (very low certainty).

1 finding from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
OR 2.74 [0.1, 74.87]
1 study · 22 participants
Very low